Related Experiment Video
Updated: Apr 14, 2026
10:39
Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
13.4K
Preparing Adjuvanted Nanoliposomes for Applications Toward Recombinant Influenza Vaccine Development
Zachary R Sia1, Wei-Chiao Huang2,3, Matthew Willadsen2,3
1Deparment of Anesthesiology, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA.
Bio-Protocol
|April 13, 2026
Summary
This study details a new method for creating nanoparticle vaccines using liposomes decorated with influenza antigens and adjuvants. This approach offers a faster, more adaptable way to produce effective flu vaccines without using eggs.
Area of Science:
- Vaccinology
- Nanotechnology
- Immunology
Background:
- Nanoparticle vaccines offer advantages over traditional methods by enhancing antigen effectiveness.
- Various nanoparticle formulations exist for diverse biomolecular cargos, adjuvants, and disease targets.
Purpose of the Study:
- To describe a protocol for producing nanoliposomes displaying recombinant influenza antigens.
- To incorporate monophosphoryl lipid A and QS-21 adjuvants for enhanced protection against influenza.
Main Methods:
- Production of adjuvanted liposomes with incorporated lipid A and QS-21.
- Coupling of His-tagged recombinant influenza antigens to the liposome surface.
- Utilizing cobalt-porphyrin phospholipid for flexible protein binding.
Main Results:
- A rapid methodology for producing immunogenic antigen-presenting liposomes.
- Tailored display of multiple influenza surface antigens on a single nanoparticle.
- Development of an egg-free vaccine production protocol.
Conclusions:
- The described protocol enables rapid production of adaptable, immunogenic nanoparticle influenza vaccines.
- This in vitro method eliminates the need for traditional virus growth in eggs.
- The platform allows for customization of vaccine formulations for specific influenza strains.
